RT Journal Article
T1 Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).
A1 López-Sánchez, C
A1 Valcárcel, D
A1 Gómez, V
A1 López-Jiménez, J
A1 Serrano, D
A1 Rubio, V
A1 Solano, C
A1 Vázquez, L
A1 Ruiz, I
A1 Grupo Español de Trasplante Hematopoyético (GETH), 
K1 Stem cell transplantation
K1 micafungin
K1 prophylaxis
AB The fungal infections remain an important problem in the allogeneic stem cell trasnsplantation (allo-SCT) setting and thus, anti-fungal prophylaxis is commonly used. The antifungal drug should offer activity, at least against Candida and Aspergillus spp., a good safety profile and low probability interactions. Micafungin could theoretically fulfill these requisites. The aim of the study was to describe the experience with micafungin as primary prophylaxis in patients undergoing allo-SCT in a cohort of Spanish centres, and to evaluate its efficacy and tolerability in this population. Retrospective multicentre observational study including all consecutive adult patients admitted for allo-SCT in participating centres of the Grupo Español de Trasplante Hematopoyético (GETH), from January 2010 to December 2013, who received micafungin as primary prophylaxis during the neutropenic period. A total of 240 patients from 13 centres were identified and 159 patients were included for the analysis. Most patients (95.6%) received 50 mg/day of micafungin. During the follow-up, 7 (4.4%) patients developed breakthrough invasive fungal disease, 1 proven and 6 probable; one patient discontinued the drug because of serious drug interactions. Prophylaxis with micafungin was considered effective in 151 (94.9%) patients. According to our experience, micafungin is an appropriate alternative for antifungal prophylaxis in patients undergoing an allo-HSCT, because its efficacy, its low profile of drug interactions and side-effects.
YR 2020
FD 2020-02-14
LK http://hdl.handle.net/10668/15105
UL http://hdl.handle.net/10668/15105
LA en
DS RISalud
RD Apr 8, 2025